KR101512386B1 - 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 - Google Patents

미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 Download PDF

Info

Publication number
KR101512386B1
KR101512386B1 KR1020080032673A KR20080032673A KR101512386B1 KR 101512386 B1 KR101512386 B1 KR 101512386B1 KR 1020080032673 A KR1020080032673 A KR 1020080032673A KR 20080032673 A KR20080032673 A KR 20080032673A KR 101512386 B1 KR101512386 B1 KR 101512386B1
Authority
KR
South Korea
Prior art keywords
metformin
mitiglinide
layer
pharmaceutically acceptable
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020080032673A
Other languages
English (en)
Korean (ko)
Other versions
KR20090107262A (ko
Inventor
한진우
이석
김영훈
Original Assignee
제이더블유중외제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이더블유중외제약 주식회사 filed Critical 제이더블유중외제약 주식회사
Priority to KR1020080032673A priority Critical patent/KR101512386B1/ko
Priority to PCT/KR2009/001809 priority patent/WO2009125975A2/ko
Priority to CN2009801124437A priority patent/CN101990427A/zh
Priority to JP2011503905A priority patent/JP2011516544A/ja
Priority to TW098111635A priority patent/TW200946111A/zh
Publication of KR20090107262A publication Critical patent/KR20090107262A/ko
Application granted granted Critical
Publication of KR101512386B1 publication Critical patent/KR101512386B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020080032673A 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 Expired - Fee Related KR101512386B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
PCT/KR2009/001809 WO2009125975A2 (ko) 2008-04-08 2009-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
CN2009801124437A CN101990427A (zh) 2008-04-08 2009-04-08 米格列奈及二甲双胍的复合制剂及其制造方法
JP2011503905A JP2011516544A (ja) 2008-04-08 2009-04-08 ミチグリニドおよびメトホルミンの複合製剤並びにその製造方法
TW098111635A TW200946111A (en) 2008-04-08 2009-04-08 Complex formulation comprising metformin and mitiglinide, and method for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080032673A KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020150040676A Division KR101591357B1 (ko) 2015-03-24 2015-03-24 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Publications (2)

Publication Number Publication Date
KR20090107262A KR20090107262A (ko) 2009-10-13
KR101512386B1 true KR101512386B1 (ko) 2015-04-17

Family

ID=41162388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080032673A Expired - Fee Related KR101512386B1 (ko) 2008-04-08 2008-04-08 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법

Country Status (5)

Country Link
JP (1) JP2011516544A (enExample)
KR (1) KR101512386B1 (enExample)
CN (1) CN101990427A (enExample)
TW (1) TW200946111A (enExample)
WO (1) WO2009125975A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
BR112012011726A2 (pt) * 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
JP6093699B2 (ja) * 2010-07-06 2017-03-08 ヤンセン ファーマシューティカ エヌ．ベー． 糖尿病のコ−セラピー治療のための製剤
KR101441355B1 (ko) * 2013-05-29 2014-09-17 주식회사 다림바이오텍 레파글리니드 및 메트포르민을 함유하는 이층정 및 그의 제조방법
JP7680822B2 (ja) * 2017-08-08 2025-05-21 日本ケミファ株式会社 糖尿病治療剤
CN110840855B (zh) * 2019-11-27 2022-04-12 哈尔滨珍宝制药有限公司 依托考昔片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2269297T3 (es) * 2000-10-30 2007-04-01 Ortho-Mcneil Pharmaceutical, Inc. Combinacion terapeutica que contiene agentes antidiabeticos y anticonvulsivos.
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043853A1 (es) * 2005-10-12 2007-04-19 World-Trade Import-Export, Wtie, Ag. Composiciones farmacéuticas que comprenden sustan- cias antidiabéticas combinadas para su uso en diabete mellitus

Also Published As

Publication number Publication date
WO2009125975A2 (ko) 2009-10-15
JP2011516544A (ja) 2011-05-26
CN101990427A (zh) 2011-03-23
KR20090107262A (ko) 2009-10-13
WO2009125975A3 (ko) 2009-12-03
TW200946111A (en) 2009-11-16

Similar Documents

Publication Publication Date Title
KR101209319B1 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
EP2986280B1 (en) Sustained-release formulations of colchicine and methods of using same
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
CN101534798B (zh) 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
JP2012530135A (ja) ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物
KR101512386B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
EP4112047B1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
KR101502031B1 (ko) 약제학적 복합제제
KR101882946B1 (ko) 모사프리드와 라베프라졸의 복합제제
EP2533767A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
CA2777231A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
KR101272470B1 (ko) 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
TWI606848B (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
CN115813874B (zh) 一种口服三方组合降糖双释片的制备方法及其制剂
KR101265491B1 (ko) 사포그릴레이트염산염을 함유하는 용출률이 조절된 경구용 다층정제 및 이의 제조방법
KR101591357B1 (ko) 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
JP2024524113A (ja) シタグリプチン、ダパグリフロジン及びメトホルミンを含む経口用複合錠剤
IL190511A (en) Delayed formulation for Pralencazen
WO2024263130A1 (en) A pharmaceutical formulation comprising linagliptin, metformin and a sglt-2 inhibitor
HK40076733A (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A16-div-PA0107

St.27 status event code: A-0-1-A10-A18-div-PA0107

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20180410

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20190221

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20230410

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230410

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000